Drug intelligence / Profile preview

YHC1150

Development stage: Preclinical
Lead developer: Yuhan

Overview

YHC1150 is a preclinical-stage drug candidate being developed by Yuhan Corporation for the treatment of solid tumors. It is part of Yuhan's early-stage oncology pipeline, which includes a variety of assets currently undergoing foundational research to evaluate their therapeutic potential. As of the current reporting, YHC1150 is in the preclinical phase, and specific details regarding its molecular target, mechanism of action, and modality have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on YHC1150.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YHC1150.

Explore the full profile